K. Barr

发表

FK506-binding protein (FKBP) partitions a modified HIV protease inhibitor into blood cells and prolongs its lifetime in vivo

G. Crabtree, J. Gestwicki, M. Mutz, 2009, Proceedings of the National Academy of Sciences.

Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists.

M. Arkin, S. Prabhu, W. Shen, 2011, Bioorganic & medicinal chemistry letters.

Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists.

M. Arkin, K. Huen, B. Cunningham, 2010, Bioorganic & medicinal chemistry letters.

Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.

M. Arkin, S. Prabhu, W. Shen, 2012, ACS medicinal chemistry letters.

Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent.

S. Ng, P. Kovar, S. Rosenberg, 2002, Bioorganic & medicinal chemistry letters.

Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation.

S. Rosenberg, R. B. Credo, H. Sham, 2002, Journal of medicinal chemistry.

Discovery and Optimization of Quinolinone Derivatives as Potent, Selective and Orally Bioavailable mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.

Mark T. Kershaw, S. Ashwell, K. Bair, 2019, Journal of medicinal chemistry.

Vinylogous Mannich Reactions. The Asymmetric Total Synthesis of (+)-Croomine

S. Martin, K. Barr, 1996 .

APPLICATIONS OF VINYLOGOUS MANNICH REACTIONS. CONCISE ENANTIOSPECIFIC TOTAL SYNTHESES OF (+)-CROOMINE

S. Bur, S. Martin, K. Barr, 1999 .

Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents.

S. Ng, P. Kovar, S. L. Gwaltney, 2001, Bioorganic & medicinal chemistry letters.

The effects of microtubular binding agents on secretion of IgM antibody.

J. Mazié, R. Teplitz, K. Barr, 1975, Experimental cell research.

Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor.

Mark T. Kershaw, S. Ashwell, D. Walker, 2020, Journal of medicinal chemistry.

Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.

R. Fucini, I. C. Choong, Joshua C. Yoburn, 2008, Bioorganic & medicinal chemistry letters.

Allosteric inhibition of protein tyrosine phosphatase 1B

Wang Shen, Daniel A Erlanson, Christian Wiesmann, 2004, Nature Structural &Molecular Biology.

Second-generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy.

S. Ng, P. Kovar, S. Rosenberg, 1999, Journal of medicinal chemistry.

Structure of the Brachydanio rerio Polo-like kinase 1 (Plk1) catalytic domain in complex with an extended inhibitor targeting the adaptive pocket of the enzyme.

R. Fucini, K. Paulvannan, R. Elling, 2008, Acta crystallographica. Section F, Structural biology and crystallization communications.

Karyological and biochemical evidence for chromosomal dedifferentiation in neoplasia

R. Teplitz, H. Lawce, K. Barr, 2007, In Vitro.